Urinary Incontinence - Podcast Version 0:00 / 0:00 1x 0.25x 0.5x 0.75x 1x 1.25x 1.5x 1.75x 2x Urinary incontinence is defined as any involuntary leakage of urine and represents a common, distressing condition that significantly impacts quality of life. It affects individuals of all ages but is particularly prevalent in women, largely due to anatomical, hormonal, and obstetric factors. Beyond the physical inconvenience, urinary incontinence can lead to social embarrassment, reduced self-confidence, sexual dysfunction, skin complications, and increased risk of institutionalisation in older adults. Understanding the underlying type of incontinence is essential, as management strategies differ according to the predominant mechanism. There are four principal types of urinary incontinence: Urgency urinary incontinence: involuntary leakage accompanied by or immediately preceded by a sudden, compelling urge to pass urine. Stress urinary incontinence: involuntary leakage occurring with physical effort, exertion, sneezing, or coughing. Mixed urinary incontinence: features of both stress and urgency incontinence. Overflow incontinence: leakage due to chronic urinary retention, typically resulting from detrusor underactivity or bladder outlet obstruction. In women, urinary incontinence is frequently associated with detrusor overactivity (particularly in urgency incontinence) or weakened pelvic floor muscles (commonly in stress incontinence). Hormonal changes, pregnancy, childbirth, and ageing contribute significantly to pelvic floor dysfunction. Adobe stock Fig 1: Stress urinary incontinence Pathophysiology Urgency incontinence is usually caused by involuntary detrusor muscle contractions during the bladder filling phase, often referred to as overactive bladder. Stress incontinence results from urethral sphincter incompetence and pelvic floor weakness, leading to inadequate resistance during rises in intra-abdominal pressure. Overflow incontinence arises when bladder emptying is incomplete, resulting in overdistension and subsequent leakage. Pharmacological Management Drug treatment is indicated when conservative measures (bladder training, pelvic floor therapy) are insufficient. Pharmacotherapy is most effective in urgency and mixed urinary incontinence, where detrusor overactivity is the primary mechanism. The main pharmacological options for urge or mixed incontinence are: 1. Antimuscarinic Agents Examples: oxybutynin, solifenacin, tolterodine, darifenacin, fesoterodine, propiverine, trospium chloride These agents work by blocking muscarinic (primarily M₃) receptors in the detrusor muscle, thereby reducing involuntary bladder contractions during the storage phase. This increases bladder capacity and reduces urgency and frequency episodes. Common adverse effects include dry mouth, constipation, blurred vision, and cognitive impairment, particularly in older adults due to anticholinergic burden. 2. β3-Adrenoceptor Agonists β₃-adrenoceptor agonists, such as mirabegron and vibegron, stimulate β₃ receptors in the detrusor muscle, promoting relaxation during the filling phase and increasing functional bladder capacity. These agents are often used as an alternative to antimuscarinics in patients who cannot tolerate anticholinergic side effects or in whom such effects are contraindicated. They are generally better tolerated but may be associated with hypertension and require blood pressure monitoring. Summary Urinary incontinence is a multifactorial and highly prevalent condition, particularly among women, with significant physical, psychological, and social consequences. Accurate identification of the type of incontinence is crucial to guide effective management. While conservative strategies remain first-line therapy, pharmacological treatment plays a central role in urgency and mixed urinary incontinence, targeting detrusor overactivity through antimuscarinic agents or β₃-adrenoceptor agonists. Frequent questions What is urinary incontinence? Urinary incontinence is the involuntary leakage of urine, which can significantly affect an individual's quality of life. It is a common condition that can occur in people of all ages, but is particularly prevalent among women due to various anatomical and hormonal factors. What are the main types of urinary incontinence? The four primary types of urinary incontinence are urgency urinary incontinence, stress urinary incontinence, mixed urinary incontinence, and overflow incontinence. Each type has distinct characteristics, such as involuntary leakage with a sudden urge or during physical exertion. What causes urgency urinary incontinence? Urgency urinary incontinence is typically caused by involuntary contractions of the detrusor muscle during the bladder filling phase, often referred to as overactive bladder. This condition leads to a sudden and compelling urge to urinate, resulting in involuntary leakage. How is stress urinary incontinence managed? Stress urinary incontinence is managed through conservative measures like pelvic floor therapy and bladder training, with pharmacological treatment considered when these approaches are insufficient. Medications may include antimuscarinic agents that help improve bladder control by reducing involuntary contractions. What role do β3-adrenoceptor agonists play in treating urinary incontinence? β3-adrenoceptor agonists, such as mirabegron, are used to treat urgency and mixed urinary incontinence by promoting relaxation of the detrusor muscle during the bladder filling phase. They serve as an alternative to antimuscarinic agents, particularly for patients who experience adverse effects from anticholinergics. Rate This Article